Literature DB >> 25483661

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Steffen Rausch1, Christian Schwentner, Arnulf Stenzl, Jens Bedke.   

Abstract

Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an appealing treatment modality. Curevacs' mRNA containing vaccines (RNActive®) combine the beneficial properties of sufficient antigen-expression, autologous immune-stimulation and a high flexibility with respect to production and application. CV9103 and CV9104 are novel RNActive®-derived anticancer vaccines for the treatment of patients with prostate cancer. After successful phase I/II studies with documentation of good tolerability and favorable immune-activation of CV9103, the vaccine CV9104 is currently undergoing clinical testing in specific clinical settings such as castration resistant prostate cancer and as a neoadjuvant agent in men with high risk prostate cancer prior to surgery. This review discusses the available preclinical and clinical data on the anticancer vaccination treatment with RNActive®-derived anticancer-vaccines CV9103 and CV9104.

Entities:  

Keywords:  CRPC; RNActive; immunotherapy; mRNA; metastatic; prostate cancer; vaccination

Mesh：

Substances：

Year:  2014        PMID： 25483661      PMCID： PMC4514038          DOI： 10.4161/hv.29553

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  48 in total

1.  RNA sex.

Authors:  Andres Jäschke; Mark Helm
Journal:  Chem Biol       Date:  2003-12

2.  Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

Authors:  James L Gulley; Christopher R Heery; Ravi A Madan; Beatriz A Walter; Maria J Merino; William L Dahut; Kwong-Yok Tsang; Jeffrey Schlom; Peter A Pinto
Journal:  Cancer Immunol Immunother       Date:  2013-07-09       Impact factor: 6.968

3.  Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database.

Authors:  G D Grossfeld; D M Stier; S C Flanders; J M Henning; W Schonfeld; K Warolin; P R Carroll
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

Review 4.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

5.  Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.

Authors:  Arthur Machlenkin; Adrian Paz; Erez Bar Haim; Ofir Goldberger; Eran Finkel; Boaz Tirosh; Ilan Volovitz; Ezra Vadai; Gilles Lugassy; Shmuel Cytron; Francois Lemonnier; Esther Tzehoval; Lea Eisenbach
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

Authors:  Ying Waeckerle-Men; Edith Uetz-von Allmen; Markus Fopp; Roger von Moos; Christel Böhme; Hans-Peter Schmid; Daniel Ackermann; Thomas Cerny; Burkhard Ludewig; Marcus Groettrup; Silke Gillessen
Journal:  Cancer Immunol Immunother       Date:  2006-04-13       Impact factor: 6.968

7.  Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

Authors:  Douglas G McNeel; Edward J Dunphy; James G Davies; Thomas P Frye; Laura E Johnson; Mary Jane Staab; Dorothea L Horvath; Jane Straus; Dona Alberti; Rebecca Marnocha; Glenn Liu; Jens C Eickhoff; George Wilding
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 8.  The control of the specificity of CD4 T cell responses: thresholds, breakpoints, and ceilings.

Authors:  Andrea J Sant; Francisco A Chaves; Scott A Leddon; Jacqueline Tung
Journal:  Front Immunol       Date:  2013-10-23       Impact factor: 7.561

Review 9.  Replicable and recombinogenic RNAs.

Authors:  Alexander B Chetverin
Journal:  FEBS Lett       Date:  2004-06-01       Impact factor: 4.124

10.  A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

Authors:  M Pavlenko; A-K Roos; A Lundqvist; A Palmborg; A M Miller; V Ozenci; B Bergman; L Egevad; M Hellström; R Kiessling; G Masucci; P Wersäll; S Nilsson; P Pisa
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640
View more
  28 in total

Review 1.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

Authors:  Piotr S Kowalski; Arnab Rudra; Lei Miao; Daniel G Anderson
Journal:  Mol Ther       Date:  2019-02-19       Impact factor: 11.454

Review 2.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

3.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

4.  Identification of personalized neoantigen-based vaccines and immune subtype characteristic analysis of glioblastoma based on abnormal alternative splicing.

Authors:  Zhifang Deng; Peiyan Zhan; Ke Yang; Li Liu; Jue Liu; Wenqi Gao
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 5.  mRNA vaccines: Past, present, future.

Authors:  Mia Karam; Georges Daoud
Journal:  Asian J Pharm Sci       Date:  2022-06-30       Impact factor: 9.273

6.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

7.  Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.

Authors:  Ans De Beuckelaer; Charlotte Pollard; Sandra Van Lint; Kenny Roose; Lien Van Hoecke; Thomas Naessens; Vimal Kumar Udhayakumar; Muriel Smet; Niek Sanders; Stefan Lienenklaus; Xavier Saelens; Siegfried Weiss; Guido Vanham; Johan Grooten; Stefaan De Koker
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

Review 8.  mRNA-Based Vaccines.

Authors:  Frank Kowalzik; Daniel Schreiner; Christian Jensen; Daniel Teschner; Stephan Gehring; Fred Zepp
Journal:  Vaccines (Basel)       Date:  2021-04-15

Review 9.  Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine-Specific Cancer Targeting with Undetectable Toxicity.

Authors:  Daniel W Binzel; Xin Li; Nicolas Burns; Eshan Khan; Wen-Jui Lee; Li-Ching Chen; Satheesh Ellipilli; Wayne Miles; Yuan Soon Ho; Peixuan Guo
Journal:  Chem Rev       Date:  2021-05-26       Impact factor: 72.087

Review 10.  From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.